Best Practice & Research Clinical Haematology

Papers
(The median citation count of Best Practice & Research Clinical Haematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
COVID-19 disease and immune dysregulation36
Immunologic effects on the haematopoietic stem cell in marrow failure25
The promise of macrophage directed checkpoint inhibitors in myeloid malignancies20
CD33 directed bispecific antibodies in acute myeloid leukemia20
Immune checkpoint inhibitors in acute myeloid leukemia19
COVID-19 and antiphospholipid antibodies18
Perspectives on current survival and new developments in AML17
Treatment of telomeropathies17
Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax16
TCR gene-engineered cell therapy for solid tumors14
Congenital amegakaryocytic thrombocytopenia – Not a single disease14
COVID-19 and HSCT (Hematopoietic stem cell transplant)14
CD123 bi-specific antibodies in development in AML: What do we know so far?13
Distinguishing constitutional from acquired bone marrow failure in the hematology clinic13
Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome12
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?12
Blood coagulation and cancer genes12
Have any strategies in Ph-like ALL been shown to be effective?12
New targets for CAR T therapy in hematologic malignancies11
Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage11
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia11
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults10
Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults10
Somatic mosaicism in inherited bone marrow failure syndromes10
Thrombosis and bleeding in hematological malignancy10
Toxicities associated with adoptive cellular therapies10
Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia10
Mechanisms of thrombosis in pancreatic ductal adenocarcinoma10
GATA2 and marrow failure8
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents8
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?8
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?8
Vaccine-induced immune thrombotic thrombocytopenia7
Antibody based therapy in relapsed acute lymphoblastic leukemia7
Overcoming graft failure after haploidentical transplantation: Is this a possibility?7
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults7
Clinical experience of CAR T cells for multiple myeloma7
How old is too old for a transplant?6
Clonal hematopoiesis and bone marrow failure syndromes6
Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?6
Dysregulation of Protein S in COVID-195
Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL)5
Advances in CAR design5
Changing trends in the therapy of acute myeloid leukemia5
Myeloproliferative neoplasms in adolescents and young adults5
Bone marrow transplantation for acquired aplastic anemia: What's new5
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?5
Challenges in anticoagulation for patients with brain tumors5
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma5
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care5
Accelerated and blast phase myeloproliferative neoplasms5
Coagulopathy in COVID-19 and anticoagulation clinical trials5
Marrow failure and aging: The role of “Inflammaging”5
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia4
Advances in polycythemia vera and lessons for acute leukemia4
A review of latest clinical practice guidelines for the management of cancer-associated thrombosis4
Monoclonal antibodies in frontline acute lymphoblastic leukemia4
It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS4
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma4
Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome3
Financial toxicity in patients with leukemia undergoing hematopoietic stem cell transplantation: A systematic review3
Molecular alterations governing predisposition to myelodysplastic syndromes: Insights from Shwachman-Diamond syndrome3
Progress in the management of chronic GVHD insights into novel therapies to treat and manage GVHD lasting longer than 12 Months3
Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps3
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program3
Addressing symptom burden in myeloproliferative neoplasms3
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia3
Graft versus Leukemia in 20233
Which novel agents will have a clinically meaningful impact in AML at diagnosis?3
What are the molecular mechanisms driving the switch from MPNs to leukemia?3
Handling missing covariate data in clinical studies in haematology3
The role of randomized controlled trials, registries, observational databases in evaluating new interventions3
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-193
A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition3
The potential role of Bi-specific antibodies in acute myeloid leukemia3
A perspective on the sickle cell disease international COVID-19 registry3
What is the role of the bone marrow microenvironment in AML?3
How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?3
Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry3
Principles of cost-effectiveness studies and their use in haematology2
Improving clinical trials in higher-risk myelodysplastic syndromes2
Thrombopoietin receptor agonists for marrow failure: A concise clinical review2
CAR T in adult ALL: When and for whom?2
Transplantation algorithm for myelofibrosis in 2022 and beyond2
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances2
Cancer associated thrombosis in pediatric patients2
Is the current consolidation regimen for AML evidence-based?2
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma2
Treatment modalities in cancer-associated venous thromboembolism (VTE)2
Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma2
Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults2
What is relative survival and what is its role in haematology?2
Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approach2
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms2
Hypomethylating agents as maintenance therapy following allogeneic hematopoietic cell transplantation for myeloid malignancies2
Since everyone has a donor, why are some eligible patients still not transplanted?2
Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?2
HLA-DM and HLA-DO interplay for the peptide editing of HLA class II in healthy tissues and leukemia2
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia1
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia1
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies1
How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML1
WHO, what, when, where, and why: New classification systems for acute myeloid leukemia and their impact on clinical practice1
Bone marrow failure syndromes1
Clinical experience of CAR T cell therapy in lymphomas1
Cytomegalovirus in haematopoietic cell transplantation - The troll is still there1
COVID-19 outcomes in sickle cell disease and sickle cell trait1
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation1
Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation1
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry1
Hodgkin lymphoma: Focus on evolving treatment paradigms1
Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors1
How can we incorporate molecular data into the IPSS?1
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders1
Diagnosis and management of cutaneous lymphomas and lymphoid proliferations in children, adolescents and young adults (CAYA)1
Is there an optimal adjunct therapy to traditional cytotoxic induction?1
Cardio-oncology and transplantation for acute myeloid leukemia1
Acute GVHD: New approaches to clinical trial monitoring1
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy1
Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease1
HLA structure and function in hematopoietic-cell transplantation1
Will immunotherapy lead to a breakthrough in the treatment of older adults with ALL?1
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?1
Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation1
Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis1
Redox stress in COVID-19: Implications for hematologic disorders1
Considerations to comprehensive care for the older individual with myelofibrosis1
Using real-world evidence in haematology1
Recent progress in acute leukemia and myelodysplasia1
Managing older adults with Ph-negative ALL: What is new? Recent advances in treating older adults with ALL1
Cytogenetics and molecular genetics of myelodysplastic neoplasms1
Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?1
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL1
The international cooperative Gaucher group (ICCG) Gaucher registry1
Novel therapeutic targets for chronic myelomonocytic leukemia1
When will chemotherapy be replaced in upfront induction therapy for adult acute lymphoblastic leukemia (ALL)?1
From clones to immunopeptidomes: New developments in the characterization of permissive HLA-DP mismatches in hematopoietic cell transplantation1
The most frequent HLA alleles around the world: A fundamental synopsis1
Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation1
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”1
Contemporary and future strategies in polycythemia vera1
Preface1
0.020811080932617